PCOS Healthcare Trends · Evergreen explainer
The four PCOS/PMOS phenotypes: why two cases look nothing alike
It is one of the most confusing moments after a PCOS diagnosis: you compare notes with a friend who has the same condition and realise your pictures barely overlap. She has irregular cycles and an ultrasound finding but no acne or excess hair. You have regular cycles, stubborn acne, and the same ultrasound finding. A third person has all three features at once. All three diagnoses can be correct. PCOS — now also called PMOS, for polyendocrine metabolic ovarian syndrome — is diagnosed when any two of three features are present, and those features combine into four recognised patterns, called phenotypes. This piece explains the four patterns in plain language, what research comparing them actually found, and why your phenotype is context for a conversation — not a score, and not a treatment plan.
The three features everything is built from
As our explainer on how PCOS/PMOS is diagnosed sets out, an adult diagnosis under the framework that began with the 2003 Rotterdam consensus — and that the 2023 International Evidence-based Guideline kept — rests on three features, after other causes that can look similar have been considered:
- Androgen excess (clinicians say hyperandrogenism): signs you can see, such as excess hair growth, hormonal acne or scalp thinning, and/or raised androgen levels on a blood test. Our glossary explains androgens in plain language.
- Irregular or absent ovulation (ovulatory dysfunction): usually visible as cycles that are very long, very variable, or missing for stretches of time.
- A polycystic pattern on ultrasound (polycystic ovarian morphology): many small follicles on an ovary, or a larger ovarian volume, using the thresholds the 2023 guideline sets. These are follicles, not cysts in the everyday sense. In adults, the guideline also allows an AMH blood result to stand in for this feature in the way it specifies.
Any two of the three are enough for the diagnosis. Three features, taken two or three at a time, make exactly four combinations. Researchers label those combinations A, B, C and D — a labelling convention that came out of a 2012 National Institutes of Health workshop on this condition and is now used across the research literature.
The four phenotypes, one by one
- Phenotype A — all three features. Androgen excess, irregular ovulation, and the polycystic ultrasound pattern together. This is the pattern most people picture when they hear the condition’s name, and in clinic-based studies it is often the largest group.
- Phenotype B — androgen excess + irregular ovulation, without the ultrasound pattern. The ovaries do not show the polycystic pattern, and that changes nothing about the diagnosis: two features are present, and the guideline’s shortcut logic applies — when irregular cycles and androgen excess are both present, the diagnosis can rest on those two.
- Phenotype C — androgen excess + the ultrasound pattern, with broadly regular cycles. Sometimes called ovulatory PCOS in the literature. Because cycles stay regular, this pattern is often recognised through skin and hair features first, and it is one reason a person can be told “your periods are fine, so it can’t be PCOS” and still meet the rule.
- Phenotype D — irregular ovulation + the ultrasound pattern, without androgen excess. No acne, excess hair or scalp thinning driven by androgens, and no raised androgens on blood tests. This is the pattern most likely to be waved off, because the visible androgen signs many people associate with the condition are absent.
One honest caution about the letters: a phenotype is a snapshot of which features were found at assessment. Features can be recorded differently at different ages and life stages, and the letter is a research and record-keeping shorthand — it is not a grade of how “real” a diagnosis is. All four patterns are the same condition, diagnosed by the same rule.
What studies found when they compared the groups
Because the four patterns differ in which features are present, researchers have asked whether they also differ, on average, in metabolic measures. Two recent studies show both the findings and the limits:
- A 2026 prospective study in the Journal of Clinical Medicine enrolled 261 women with PCOS and grouped them by phenotype (A: 101, B: 39, C: 55, D: 66). The researchers reported that insulin resistance, defined by a HOMA-IR cut-off, was recorded in 58.3% of phenotype A, 56.4% of B, 49.1% of C and 22.6% of D in that study group, and that average HOMA-IR was lowest in phenotype D. The authors themselves stated the key limit plainly: these are cross-sectional differences measured at one point in time, and they should not be read as evidence about any individual’s future risk.
- A 2025 study in Medicina compared a visceral adiposity index — a calculated marker researchers use as a stand-in for deep abdominal fat — across 180 patients and 51 controls. The authors reported higher average index values in the groups with both androgen excess and irregular ovulation (phenotypes A and B) than in C and D, and a higher frequency of metabolic syndrome in phenotype A in that sample. It is one sample, from one setting, using a calculated index rather than direct measurement — useful as part of a pattern across studies, not as a personal verdict.
Read together with the older review literature, the broad shape researchers describe is that the patterns carrying androgen excess — A and B most consistently — tend to show less favourable metabolic averages than D, with C usually in between. Three fences belong around that sentence. First, these are group averages: every phenotype group in these studies contained people above and below its average. Second, most of this evidence is cross-sectional — a snapshot, not a follow-up — so it describes association, not destiny. Third, none of it changes the screening floor: the 2023 guideline recommends assessing glucose status at diagnosis and re-checking it over time for people with this condition regardless of BMI, as our explainers on insulin resistance and lean PCOS set out — and it does not carve out a phenotype that skips that assessment.
Not the same thing as the “types of PCOS” lists online
Search for “types of PCOS” and you will meet two different lists wearing the same word. One is the A-to-D phenotypes above: diagnostic patterns, defined by which of the three features are present. The other is a set of labels circulating in blogs and social posts — “adrenal PCOS,” “inflammatory PCOS,” “post-pill PCOS” and similar — that describe proposed contributors or the circumstances around when symptoms were noticed. Top-ranking explainers that separate the two make the same point: those contributor labels are not diagnostic categories in the Rotterdam framework or the 2023 guideline, they do not replace the 2-of-3 assessment, and a person still needs the same workup — including considering other causes that can mimic the condition — whatever label brought them in. If a label you have read about matters to you, it is a reasonable thing to raise at an appointment; it is the clinician’s job to map it onto the actual assessment.
Questions to ask about your own pattern
- Which of the three features were found in my case, and which were absent or unclear? Can that be written into my record in plain words, not only as a letter?
- If my letter was recorded, which phenotype is it — and what, if anything, does it change about what we monitor?
- Has my glucose status been assessed, and when are glucose, lipids and blood pressure due to be re-checked — who owns those dates?
- If I have no androgen signs (the phenotype D pattern), what should I still expect to be followed over time?
- If my cycles are regular (the phenotype C pattern), how will the other features be tracked so the picture does not get lost between visits?
- Could my recorded pattern change — for example with age, or after pregnancy — and if it does, what would we actually do differently?
- Who coordinates my care overall? Our piece on which clinician does what maps the team this condition often involves.
What this does not mean
- A phenotype is not a severity score. D is not “PCOS-lite” and A is not a sentence. Fertility, skin, mood, sleep and metabolic questions can be pressing in any pattern, and quiet in any pattern.
- A phenotype is not a treatment plan. This page names no treatments and ranks none. What fits a person depends on their full picture and priorities, decided with their clinician.
- Your friend’s case is not your template. Different feature combinations are the expected shape of this condition, not a sign that one of you was misdiagnosed.
- You cannot reliably self-assign a phenotype. Two of the three features need examination findings, blood tests or an ultrasound read against guideline thresholds — and other causes have to be considered first.
What this means when you are finding care
The clinician you want is the one who can tell you which features they found, which they ruled out, and what follow-up travels with your pattern — in words, not just a letter. You can search the directory for PCOS/PMOS-focused providers by state, provider type and telehealth, browse by state — for example the Florida listings page — and skim the plain-language glossary before a visit.
Sources
- Recommendations from the 2023 International Evidence-based Guideline for the Assessment and Management of Polycystic Ovary Syndrome, Journal of Clinical Endocrinology & Metabolism, 2023 — read the guideline (PMC)
- Phenotype-Specific Differences in Insulin Resistance and Androgenic Profiles in Polycystic Ovary Syndrome: A Prospective Observational Study, Journal of Clinical Medicine, 2026 — read the study (PMC)
- Akkus C, et al. Visceral Adiposity Index (VAI) Levels and Metabolic Risk Across Phenotypes of Polycystic Ovary Syndrome (PCOS), Medicina, 2025 — read the study (PMC)
- Moran L, Teede H. Metabolic features of the reproductive phenotypes of polycystic ovary syndrome, Human Reproduction Update, 2009 — read the review abstract (PubMed)
- The guideline program’s home at Monash University — Monash Centre for Health Research and Implementation — PCOS
- Federal overview of the condition — NICHD — PCOS topic page
- Top-ranking explainer used as the bar for this piece — AppsHealthy — Types of PCOS: Rotterdam phenotypes vs myths
Looking for care? Find a PCOS/PMOS-focused provider or browse by state.
This article is general information published by the PMOS Directory. It is not medical advice and is not a substitute for professional medical advice, diagnosis, or treatment. It does not describe what any treatment does for any person, and it is not a recommendation for or against any treatment, product, or provider. Always seek the advice of your physician or other qualified health provider with any questions about a medical condition. If this is an emergency, call 911.